Previous close | 10.50 |
Open | 10.50 |
Bid | 3.40 |
Ask | 13.00 |
Strike | 640.00 |
Expiry date | 2025-01-17 |
Day's range | 10.50 - 10.50 |
Contract range | N/A |
Volume | |
Open interest | 49 |
Regeneron's (REGN) efforts to expand its oncology portfolio get a hit as the FDA refuses to approve the lymphoma drug odronextamab.
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing confirmatory trials. The FDA said in its response letter that it needs more data from enrollments in dose-finding and confirmatory portions of trials, delaying its decision on the drug, while confirming no issues with clinical efficacy or safety, trial design, labeling or manufacturing. The company was testing its experimental drug, odronextamab, in multiple late-stage trials in patients with follicular lymphoma and diffuse large B-cell lymphoma, the two most common subtypes of non-Hodgkin lymphoma.